GlassScriptPhysician profile
Fehmida Vejlani
NPI 1689641839
$1,503.19
in general payments reported to CMS, 2019-2025
19 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.96 · 2020: $117 · 2021: $77.29 · 2022: $195 · 2023: $268 · 2024: $404 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $439.80 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $294.59 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Allergan, INC. | $133.46 | 2019-2020 | |
| Amgen INC. | $95.30 | 2020-2024 | Repatha, Otezla |
| Viatris Specialty LLC | $85.05 | 2025 | Yupelri |
| Pfizer INC. | $73.85 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $72.08 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Inspire Medical Systems, INC. | $62.87 | 2023 | Inspire |
| Novo Nordisk INC | $46.96 | 2020-2022 | |
| 3b Medical, INC. | $27.28 | 2025 | Luna |
| Regeneron Healthcare Solutions, INC. | $24.04 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.91 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.68 | 2025 | Nuzyra |
| Philips North America LLC | $21.43 | 2025 | Vest Therapy Und |
| Pulmonx Corporation | $18.49 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $16.54 | 2019 | |
| Edwards Lifesciences Corporation | $16.13 | 2023 | |
| Merck Sharp & Dohme LLC | $15.34 | 2023 | Keytruda |
| Janssen Pharmaceuticals, INC | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fehmida Vejlani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.